Supreme Court of the United States

Summary

Supreme Court of the United States U.S. ex rel. Schutte v. SuperValu (2023)

Respondents make one more argument, approaching the issue from a somewhat different angle. They contend that, at common law, their claims would not be actionable as fraudulent even if their reported prices were not accurate under the correct meaning of “usual and customary.” Their argument is as follows: At common law, misrepresentations of law are not actionable; only misrepresentations of fact are. Because the FCA incorporates the common law of fraud, it embodies that same limitation.
Source: Wikisource

Supreme Court of the United States U.S. ex rel. Schutte v. SuperValu (2023)

According to petitioners, in 2006, respondents’ competitor, Walmart, began offering 30-day supplies of many drugs for $4. [2] To compete with Walmart, SuperValu and Safeway adopted price-match programs in which their pharmacies would match a competitor’s lower price at a customer’s request. SuperValu’s pharmacies would then automatically apply that price to future refills of the drug for those customers. Meanwhile, Safeway also adopted a “membership” discount program through which customers received discounted generic drug prices (often $4 for a 30-day supply) .
Source: Wikisource

Supreme Court of the United States U.S. ex rel. Schutte v. SuperValu (2023)

In certain circumstances, pharmacies are required to bill Medicare and Medicaid for their “usual and customary” drug prices. And, critically, these cases involve defendants (respondents here) who may have correctly understood the relevant standard and submitted inaccurate claims anyway. The question presented is thus whether respondents could have the scienter required by the FCA if they correctly understood that standard and thought that their claims were inaccurate.
Source: Wikisource

Get perspective with Kwize: daily news enlightened by great literature